Search PubMed⌕ Search

Biomedical subjects

J Havelka

Publications and source records attributed to J Havelka.

At least 55 records · Page 3Linked to original sources

Some effects of triamcinolone pretreatment on intravenous glucose tolerance test in patients with different thyroid function.

In 42 patients (17 hypothyroid -Hypo, 14 euthyroid -Eu and 11 thyrotoxic -TX) the intravenous glucose tolerance test was performed before and after triamcinolone sensitization. The blood sugar (BS), immunoreactive insulin (IRI), growth hormone (GH), inorganic phosphorus (P), calcium (Ca), and total proteins (TP) were assessed and glucose disappearance rate was calculated from absolute values (KGt) and from increments (KGi) of glucose. Triamcinolone caused a rise of BS in Eu an Tx subgroups and a decrease of KGt and KGi in Hypo and decrease of KGt in Tx. No differences were found in patterns of IRI, GH, TP and Ca, respectively, but a significant rise of P after triamcinolone was found in Hypo and Eu subgroup. When comparing the subgroups according to thyroid function, only mild differences could be demonstrated in BS pattern both during IVGTT and TIVGTT, but significant differences of KGt and KGi were found between Eu and Hypo subgroups. No differences were observed in patterns of IRI, GH and Ca (except fasting values in Eu and Hypo subgroups during IVGTT, but significant differences were found in the pattern of P and particularly of TP. Except of differences of TP and P, changes during TIVGTT were not more pronounced than those during IVGTT. The comparison of effects of triamcinolone pretreatment on IVGTT and on OGTT (as were described previously) demonstrated similar effects of triamcinolone in Eu subgroups (significant changes of BS, IRI and P), but different action in Hypo- and Tx subgroups (where the significant changes of BS, IRI and P during OGTT and IVGTT were not parallel). These findings may suggest a possible role of some gastrointestinal and/or hepatic factors in action of triamcinolone in impaired thyroid function, but not in normal persons.

Adult↗

Labelled amino acids in plasma of patients with thyrotoxicosis and thyroid cancer after radioiodine treatment.

The levels of total organically bound 131I, per cent of labelled iodoproteins, total labelled iodinated amino acids and a percentage of individual iodinated amino acids (thin-layer chromatography) were measured in serum of 84 patients with thyroid cancer and of 16 patients with thyrotoxicosis at 48 h after the administration of therapeutic dose of 131I. In thyrotoxic patients treated with therapeutic doses of 131I (2 to 39.6mCi; 74 to 1500 MBq) the findings were similar to normal subjects. In patients with thyroid cancer a significant increase of iodotyrosines was found after thyroid radioiodide ablation (100 to 200 mCi; 3.7 to 7.4 GBq). No remarkable differences were found between two groups of patients with thyroid cancer, the first one being treated with thyroid eliminating dose in attempt to activate the metastases of functionally differentiated tumour, while the second one was treated with similar doses (i. e. 100 to 200 mCi) to suppressor destroy a functionally active tumour or its metastases. Even though the hormonogenesis in tumours was hardly distinguishable from the products of its radiation damage, it was suggested that the hormonogenesis in neoplastic tissue differs from that in normal thyroid only quantitatively, being less in patients with thyroid cancer than in these with thyrotoxicosis.

Amino Acids↗